Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-01 in r/r CD7+ T-ALL/T-LBL
NCT04620655Phase 1Unknown
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-01 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL). Primary endpoint: Dose-limiting toxicity at 4 weeks. Status: unknown.
02
Drugs
RD13-01
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04620655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620655.